News
Protembis gets €20 million EIB backing
New financing for Protembis to accelerate ‘research and development’ programs, global ‘market access’ initiatives, and to complete the pivotal FDA clinical trial.
Learn more
Discover News & Press
First Patient Enrolled in the PROTEMBO IDE Pivotal Trial
Only CEP trial designed as a superiority trial using DW-MRI to demonstrate effectiveness against the currently approved Sentinel device.
Learn more
Protembis Completes €30M Financing and Adds Keith D. Dawkins to Board
Financing and Reinforcement of Board of Directors Builds Momentum in Readiness for the Initiation of the IDE Pivotal Trial.
Learn more
European PROTEMBO C Trial Published in EuroIntervention Journal
New published European clinical evidence builds momentum for the FDA approved Pivotal PROTEMBO clinical trial.
Learn more
FDA Approval of Pivotal Investigational Device Exemption (IDE) Study
Novel Adaptive Superiority Trial Design of ProtEmbo® Cerebral Embolic Protection (CEP) System.
Learn more
Professor J Mocco to Join Protembis’ Board of Directors
Protembis announces the appointment of Professor J. Mocco to Board of Directors.
Learn more
Azin Parhizgar To Chair Protembis’ New Board of Directors
Leadership team reinforced for next phase in Protembis’ clinical and regulatory growth trajectory.
Learn more
Protembis announces completion of 20 cases in European CE mark study
Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland.
Learn more
Protembis Successfully Closes $ 10 Million Series A Financing
Protembis Develops New Catheter-Based Filter to Protect Heart Procedure Patients from Stroke and Neurological Injuries.
Learn more
Events
Highlights from the Protembis Breakfast Symposium at TCT 2024
Protembis sponsored a satellite symposium at TCT 2024, uniting renowned co-chairs, expert speakers, and panelists to discuss key topics in cerebral protection for TAVR.
